The 28 references in paper O. Pylaeva A., K. Mukhin Yu., О. Пылаева А., К. Мухин Ю. (2015) “Применение нового антиэпилептического препарата перампанел (Файкомпа) в лечении эпилепсии (обзор зарубежной литературы) // USE OF THE NEW ANTIEPILEPTIC DRUG PERAMPANEL (FYCOMPA) IN THE TREATMENT OF EPILEPSY: A REVIEW OF FOREIGN LITERATURE” / spz:neicon:rjdn:y:2014:i:3:p:36-42

1
Elger C.E., Schmidt D. Modern management of epilepsy: а practical approach. Epilepsy Behav 2008;12(4):501–39.
(check this in PDF content)
2
Franco V., Crema F., Iudice A. et al. Novel treatment options for epilepsy: focus on perampanel. Pharmacol Res 2013;70(1): 35–40.
(check this in PDF content)
3
French J.A., Krauss G.L., Biton V. et al. Adjunctive perampanel for refractory partialonset seizures: randomized phase III study 304. Neurology 2012;79(6):589–96.
(check this in PDF content)
4
French J.A., Krauss G.L., Steinhoff B.J. et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia 2013;54(1):117–25.
(check this in PDF content)
5
Hanada T. The discovery and development of perampanel for the treatment of epilepsy. Expert Opin Drug Discov 2014;9(4):449–58.
(check this in PDF content)
6
Kerling F., Kasper B.S. Efficacy of perampanel: a review of clinical trial data. Acta Neurol Scand Suppl 2013;(197):25–9.
(check this in PDF content)
7
Ko D., Ramsay R.E. Perampanel: expanding therapeutic options for patients with medically refractory secondary generalized convulsive seizures. Acta Neurol Scand Suppl 2013;(197): 36–43.
(check this in PDF content)
8
Krauss G.L. Perampanel: a selective AMPA antagonist for treating seizures. Epilepsy Curr 2013;13(6):269–72.
(check this in PDF content)
9
Krauss G.L., Bar M., Biton V. еt al. Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol Scand 2012;125(1):8–15.
(check this in PDF content)
10
Krauss G.L., Perucca E., Ben-Menachem E. et al. Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: Results from phase III extension study 307. Epilepsia 2014;55(7):1058–68.
(check this in PDF content)
11
Krauss G.L., Perucca E., Ben-Menachem E. еt al. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partialonset seizures: interim results from phase III, extension study 307. Epilepsia 2013;54(1): 126–34.
(check this in PDF content)
12
Krauss G.L., Serratosa J.M., Villanueva V. еt al. Randomized phase III study 306: adjunctive perampanel for refractory partialonset seizures. Neurology 2012;78(18):1408–15.
(check this in PDF content)
13
Kwan P., Brodie M.J. Epilepsy after the first drug fails: substitution or add-on? Seizure 2000;9(7):464–8.
(check this in PDF content)
14
Kwan P., Brodie M.J. Refractory epilepsy: mechanisms and solutions. Expert Rev Neurother 2006;6(3):397–406.
(check this in PDF content)
15
Patsalos P.N. Drug interactions with the newer antiepileptic drugs (AEDs) – part 1: pharmacokinetic and pharmacodynamic interactions between AEDs. Clin Pharmacokinet 2013;52(11):927–66.
(check this in PDF content)
16
Patsalos P.N. Drug interactions with the newer antiepileptic drugs (AEDs) – рart 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders. Clin Pharmacokinet 2013;52(12):1045–61.
(check this in PDF content)
17
Rektor I., Krauss G.L., Bar M. et al. Perampanel Study 207: long-term open-label evaluation in patients with epilepsy. Acta Neurol Scand 2012;126(4):263–9.
(check this in PDF content)
18
Rheims S., Ryvlin P. Profile of perampanel and its potential in the treatment of partial onset seizures. Neuropsychiatr Dis Treat 2013;9:629–37.
(check this in PDF content)
19
Rogawski M.A. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr 2011;11(2):56–63
(check this in PDF content)
20
Rugg-Gunn F. Adverse effects and safety profile of perampanel: a review of pooled data. Epilepsia 2014;55 Suppl 1:13–5.
(check this in PDF content)
21
Satlin A., Kramer L.D., Laurenza A. Development of perampanel in epilepsy. Acta Neurol Scand Suppl 2013;(197):3–8.
(check this in PDF content)
22
Serratosa J.M., Villanueva V., Kerling F., Kasper B.S. Safety and tolerability of perampanel: a review of clinical trial data. Acta Neurol Scand Suppl 2013;(197):30–5. 4141 RGDN_03_2014 Block.indd 41RGDN_03_2014 Block.indd 4128.10.2014 16:15:2728.10.2014 16:15:27
(check this in PDF content)
23
Shih J.J., Tatum W.O., Rudzinski L.A. New drug classes for the treatment of partial onset epilepsy: focus on perampanel. Ther Clin Risk Manag 2013;9:285–93.
(check this in PDF content)
24
Steinhoff B.J. Efficacy of perampanel: a review of pooled data. Epilepsia 2014; 55 Suppl 1:9–12.
(check this in PDF content)
25
Steinhoff B.J., Bacher M., Bast T. еt al. First clinical experiences with perampanel – the Kork experience in 74 patients. Epilepsia 2014;55 Suppl 1:16–8.
(check this in PDF content)
26
Steinhoff B.J., Ben-Menachem E., Ryvlin P. еt al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia 2013;54(8):1481–9.
(check this in PDF content)
27
Steinhoff B.J., Hamer H., Trinka E. еt al. A multicenter survey of clinical experiences with perampanel in real life in Germany and Austria. Epilepsy Res 2014;108(5):986–8.
(check this in PDF content)
28
Zwart R., Sher E., Ping X. еt al. Perampanel, an Antagonist of α-Аmino-3Нydroxy-5-Мethyl-4-Isoxazolepropionic Acid (AMPA) Receptors for the Treatment of Ep
(check this in PDF content)